Clinically significant ILD is believed to occur in 5%-10% of patients with RA, but robust data are lacking on how to best predict which patients face the highest risk for RA-associated ILD.
Agomab Therapeutics NV: Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
GHENT, Belgium, December 14, 2023 Agomab Therapeutics NV (‘Agomab’) today announced that it has dosed the first subject in a first-in-human Phase 1 clinical study of AGMB-447, an inhaled lung-restricted small molecule inhibitor of ALK5 (TGFβRI or ALK5). The study is evaluating AGMB-447 in healthy subjects and in patients with idiopathic pulmonary fibrosis (IPF).
Global Idiopathic Pulmonary Fibrosis (IPF) Market Analysis Report 2023-2029: Enhancing R&D Operations for Development of Novel Treatments and Improving Access to Treatment lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.